Vericel SEC Filings

Vericel (VCEL) reported an insider transaction by Chief Operating Officer Michael Halpin on 11/11/2025. He exercised a stock option for 2,642 shares at $16.66 (code M) and sold 2,642 shares at $40.41 (code S). The sale was executed automatically under a Rule 10b5-1 trading plan adopted on November 19, 2024.

Following the transactions, he directly owned 15,932 shares. Derivative holdings included 56,250 stock options. The footnotes note prior shares acquired under the 2015 Employee Stock Purchase Plan and the vesting schedule of the option grant.

Vericel (VCEL) reported an insider transaction by a director on 11/10/2025. The director exercised 7,000 stock options at an exercise price of $2.63 (code M) and sold 7,000 shares at an average price of $38.59 (code S) under a Rule 10b5-1 trading plan adopted on March 11, 2024.

Following these transactions, the director reported 15,100 shares beneficially owned directly and 10,500 options remaining beneficially owned. The options exercised were part of a grant from May 3, 2017 that vested in equal monthly installments over one year contingent on continued service.

Vericel (VCEL) reported an insider transaction by Chief Operating Officer Michael Halpin. On 11/06/2025, he exercised 7,358 stock options at $16.66 per share and sold 7,358 common shares at $40.47, with the sale executed under a Rule 10b5-1 trading plan adopted on November 19, 2024.

Following the transactions, Halpin directly beneficially owned 15,932 common shares. His remaining derivative holdings included 58,892 stock options. Footnotes note prior shares acquired under the company’s 2015 Employee Stock Purchase Plan.

Vericel (VCEL) filed its Q3 2025 Form 10‑Q, reporting total revenue of $67.503 million, up 16.6% year over year, and net income of $5.074 million versus a loss in the prior year period. Gross profit was $49.585 million as MACI led growth.

Product mix shifted: MACI revenue rose to $55.662 million (up 24.6%), NexoBrid increased to $1.466 million, while Epicel declined to $10.375 million. For the nine months, revenue reached $183.341 million (up 13.3%) with a narrower net loss of $6.725 million.

Balance sheet and liquidity: Cash and cash equivalents were $100.403 million, with investments of $84.641 million. The company has a $150.0 million undrawn revolving credit facility and total shareholders’ equity of $321.858 million. Operating lease liabilities totaled $98.006 million current and long‑term combined.

Operational updates: MACI Arthro remained in market following the 2024 sBLA approval enabling arthroscopic delivery. Management highlighted Burlington, MA facility progress and continued U.S. commercialization of NexoBrid under the MediWound supply agreements.

Vericel Corporation furnished an 8-K announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.

The company states the information in this report and Exhibit 99.1 is being furnished, not filed, under the Exchange Act. Additional materials include the Inline XBRL cover page as Exhibit 104.

Jonathan Siegal, Principal Accounting Officer of Vericel Corporation (VCEL), reported securities transactions dated 09/30/2025. He received 938 shares upon vesting of restricted stock units originally granted on 09/30/2021, with a stated fair market value of $31.47 per share. To satisfy tax withholding on the vesting, 370 shares were withheld by the issuer at that same $31.47 value. The filing shows 2,440 shares beneficially owned after the RSU vesting and 2,070 shares beneficially owned following the withholding transaction. The report was signed by an attorney-in-fact on behalf of Mr. Siegal on 10/02/2025.

Vericel Corp (VCEL) insider Jonathan M. Hopper executed option-related transactions on 09/02/2025. Mr. Hopper exercised options with an $18 strike to acquire 10,000 shares and simultaneously sold 10,000 shares at $35.77 under an existing Rule 10b5-1 trading plan adopted May 30, 2025. After these transactions he beneficially owned 76,363 shares before the sale entry and 66,363 shares following the reported sale entry, reported as direct ownership. The reporting notes that some shares were acquired through the company’s 2015 Employee Stock Purchase Plan and that the underlying option grant (total right to buy 48,750 shares) vests in quarterly installments beginning May 11, 2020. The Form 4 was signed by an attorney-in-fact.

Form 144 filing for Vericel Corporation (VCEL) shows a planned sale of 10,000 common shares held by the reporting person through Fidelity Brokerage Services. The filing lists an approximate aggregate market value of $357,700 for the shares to be sold and indicates the shares represent part of an option granted on 02/11/2020 and acquired on 09/02/2025, with cash payment at exercise. The issuer's total shares outstanding are shown as 50,460,205, so the proposed block is a small fraction of the company. The filing also discloses a prior sale of 10,000 common shares by the same person on 06/02/2025 for $400,924. The notice affirms the signer does not possess undisclosed material adverse information.

Kevin F. McLaughlin, a director of Vericel Corporation (VCEL), exercised 7,000 stock options at an exercise price of $2.76 and immediately sold 7,000 common shares at $35.92 on 08/06/2025 pursuant to a Rule 10b5-1 trading plan adopted March 11, 2024.

After these transactions the filing reports beneficial ownership of 15,100 common shares. The filing also states the options originally granted on May 4, 2016 represented the right to purchase 15,000 shares and shows 0 derivative securities beneficially owned following the reported transactions.